	The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update. Epigenomics Yan LJ, Y Lau AT, Xu YM. PMID: 38639712 [PubMed - as supplied by publisher]
	The causality between Type 2 diabetes and breast cancer: a bidirectional two-sample Mendelian randomization study. Future Oncol Zhang L, Liu S, Yue G, Niu H, Hu M, Zheng Y, Tang J. PMID: 38639577 [PubMed - as supplied by publisher]
	Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial. EClinicalMedicine Liang Y, Liu J, Ge J, Shi Q, Zhang G, Wan A, Luo T, Tian H, Fan L, Wang S, Chen L, Tang P, Zhu K, Jiang J, Bian X, Zhang Y, Qi X. PMID: 38638401 [PubMed]
	Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine Llombart-Cussac A, Pérez-Garcia JM, Ruiz Borrego M, Tolosa P, Blanch S, Fernández-Ortega A, Urruticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce Lorenzo J, Gion M, Cortez-Castedo P, Llabres E, Galve E, Cueva JF, López A, Alonso-Romero JL, González-Santiago S, Martínez de Dueñas E, Ciruelos E, Martrat G, Gener P, Alcalá-López D, Sampayo-Cordero M, Gómez-Peralta F, Cortés J. PMID: 38638399 [PubMed]
	Demographic disparities in the limited awareness of alcohol use as a breast cancer risk factor: empirical findings from a cross-sectional study of U.S. women. BMC Public Health Swahn MH, Martinez P, Balenger A, Luningham J, Seth G, Awan S, Aneja R. PMID: 38637773 [PubMed - in process]
	Log odds of positive lymph nodes (LODDS)-based novel nomogram for survival estimation in patients with invasive micropapillary carcinoma of the breast. BMC Med Res Methodol Meng X, Hao F, Wang N, Qin P, Ju Z, Sun D. PMID: 38637725 [PubMed - in process]
	A Deep Learning Model for Predicting Molecular Subtype of Breast Cancer by Fusing Multiple Sequences of DCE-MRI From Two Institutes. Acad Radiol Xie X, Zhou H, Ma M, Nie J, Gao W, Zhong J, Cao X, He X, Peng J, Hou Y, Zhao F, Chen X. PMID: 38637240 [PubMed - as supplied by publisher]
	Advancing breast cancer screening: a call for updated policy and practice. Evid Based Nurs Al Hashmi I, Al Omari O. PMID: 38637147 [PubMed - as supplied by publisher]
	Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging. J Nucl Med Moser R, Pfeiffer S, Cala L, Klein E, Kiechle M, Behzadi ST, Fallenberg E, Combs SE, Weber W, Borm KJ. PMID: 38637138 [PubMed - as supplied by publisher]
	Exploratory study of using Magnetic resonance Prognostic Imaging markers for Radiotherapy In Cervix cancer (EMPIRIC): a prospective cohort study protocol. BMJ Open Abdul-Latif M, Chowdhury A, Tharmalingam H, Taylor NJ, Lakhani A, Padhani A, Hoskin P, Tsang Y. PMID: 38637128 [PubMed - in process]
	Inflammatory breast cancer biomarkers and biology. Int Rev Cell Mol Biol van Golen KL. PMID: 38637100 [PubMed - in process]
	Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis. Int Rev Cell Mol Biol Sahraoui G, Rahoui N, Driss M, Mrad K. PMID: 38637099 [PubMed - in process]
	Comprehensive understanding of the role of GPER in estrogen receptor-alpha negative breast cancer. J Steroid Biochem Mol Biol Abbas MA, Al-Kabariti AY, Sutton C. PMID: 38636681 [PubMed - as supplied by publisher]
	The Lancet Breast Cancer Commission. Lancet Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips KA, Radbruch L, Thompson MK, André F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Inbah Rajah D, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Vargas Enciso V, Vaz-Luis I, Villarreal-Garza C, Lancet Breast Cancer Commission. PMID: 38636533 [PubMed - as supplied by publisher]
	Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO Precis Oncol Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Penson RT, Stover EH, Curtis J, Sawyer H, Polak M, Chowdhury D, D'Andrea AD, Färkkilä A, Shapiro GI, Matulonis UA. PMID: 38635934 [PubMed - in process]
	Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial. PLoS One Bahçac, Atasavun Uysal S, Erdogan , Ordu Ç, Soybir GR, Ozmen V. PMID: 38635763 [PubMed - in process]
	Pistacia lentiscus L. revealed in vitro anti-proliferative activity on MCF-7 breast cancer cells and in vivo anti-mammary cancer effect on C57BL/6 mice through necrosis, anti-inflammatory and antioxidant enhancements. PLoS One Abidi O, Abdelkafi-Koubaa Z, Bettaieb-Dridi I, Toumi L, Marzouki L, Souilem O. PMID: 38635559 [PubMed - in process]
	Dual-Aptamer Recognition of DNA Logic Gate Sensor-Based Specific Exosomal Proteins for Ovarian Cancer Diagnosis. ACS Sens Zhao M, Li Q, Zhao Y, Zhou H, Yan Y, Kong RM, Tan Q, Kong W, Qu F. PMID: 38635557 [PubMed - as supplied by publisher]
	Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER. PLoS One Li N, Jin S, Wu J, Ji H, Du C, Liu B. PMID: 38635517 [PubMed - in process]
	Projected Time for the Elimination of Cervical Cancer Under Various Intervention Scenarios: Age-Period-Cohort Macrosimulation Study. JMIR Public Health Surveill Chen YC, Chen YY, Su SY, Jhuang JR, Chiang CJ, Yang YW, Lin LJ, Wu CC, Lee WC. PMID: 38635315 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 294322

Page 1 of 14717



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy